Loading clinical trials...

Neural Mechanisms of Fatigue in Post-Acute Sequela of SARS-CoV-2 | Clinical Trials | Clareo Health

RECRUITINGNA

Neural Mechanisms of Fatigue in Post-Acute Sequela of SARS-CoV-2

Motivated Decision-Making and Performance

NCT07278388•Hugo W. Moser Research Institute at Kennedy Krieger, Inc.

Summary

This proposal aims to understand the neurobiological mechanisms of fatigue in individuals with Post-Acute Sequelae of SARS-CoV-2 Infection (PASC). This knowledge will eventually provide candidate mechanisms to target with pharmacological intervention and inform rehabilitative care for those individuals suffering from symptoms of fatigue in PASC.

Eligibility

Age

18 - 75 years

Sex

ALL

Healthy Volunteers

Yes

Inclusion Criteria

•Age 18 to 75 years old.
•Have received a clinical diagnosis of post-acute sequelae of SARS-CoV-2 (PASC)/long COVID syndrome using the criteria specified by Thaweethai, et al., 2023 (JAMA). This symptom checklist provides a score based on the number and severity of symptoms. An individual with a score \>12 is classified as having PASC.
•Currently experiencing Fatigue/Brain Fog as assessed with the Post-COVID symptom checklist and the PedsQL questionnaire.

Exclusion Criteria

•Neurological disorders including, but not limited to, stroke, head injury, epilepsy, seizures, brain tumors, brain surgery, Parkinson's Disease, or any other neuromuscular disease (self-report).
•Diagnosed history of severe psychiatric diseases such as depression and schizophrenia (self-report).
•Congestive heart failure.
•Peripheral artery disease with claudication.
•Cancer.
•Pulmonary or renal failure.
•Unstable angina.
•Uncontrolled hypertension (more than 190/110 mmHg).
•Severe aphasia.
•Orthopedic or pain conditions.
+7 more criteria

Locations (1)

Kennedy Krieger Institute

Baltimore, Maryland, United States

Key Dates

Start Date

July 16, 2025

Primary Completion Date

December 31, 2029

Completion Date

December 31, 2029

Last Updated

December 12, 2025

Enrollment

200

ESTIMATED participants

Conditions

PASC Post Acute Sequelae of COVID 19Fatigue

Interventions

Physical Fatigue

BEHAVIORAL

Contacts

Anthony Gonzalez

CONTACT

443-923-2716 gonzalezan@kennedykrieger.org

Vikram Chib, PhD

CONTACT

Improving Post COVID-19 Syndrome With Hyperbaric Oxygen Treatments

NCT06082518

Post COVID-19 ConditionPost-COVID-19 Syndrome+4 more

View study

RECRUITING

Cognitive Performance, Sleep Disturbances and Fatigue in Multiple Sclerosis

NCT07426991

Multiple SclerosisRemitting-Relapsing Multiple Sclerosis+4 more

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: December 12, 2025Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Neural Mechanisms of Fatigue in Post-Acute Sequela of SARS-CoV-2

Inclusion Criteria

Exclusion Criteria

Improving Post COVID-19 Syndrome With Hyperbaric Oxygen Treatments

Cognitive Performance, Sleep Disturbances and Fatigue in Multiple Sclerosis

Assessment of N-Acetylcysteine as Therapy for Myalgic Encephalomyelitis/Chronic Fatigue Syndrome

Assessment of Neuroinflammation in Central Inflammatory Disorders Using [F-18]DPA-714.

Behavioral and Neural Representations of Subjective Effort Cost

Confirmatory Trial for Alleviating Fatigue in Multiple Sclerosis